TLDR:
- Injective TVL surged 22% in a week, climbing to $31 million across DeFi protocols.
- INJ trades near $13 with a $1.3B market cap, maintaining strength despite daily dips.
- Market analysts project mid-term INJ targets between $16 and $18 if trends continue.
- Deflationary tokenomics and utility-driven growth fuel bullish sentiment on Injective.
Injective’s DeFi ecosystem is gaining momentum as its Total Value Locked (TVL) climbed 22% in a week, reaching $31 million. This milestone marks a key development for the project, putting it ahead of peers like Abstract, Swellchain, and Metis in TVL rankings.
The steady rise suggests growing institutional interest and engagement despite broader market cooling.
Moreover, activity around Injective has strengthened as DeFi protocols shift toward sustainability and real-world use cases. The market’s recent behavior reflects a maturing phase with utility now driving capital flows.
Injective TVL Growth Pushes Injective Ahead of Rivals
According to Coinpedia Markets, Injective’s TVL rose substantially within a week, a gain that placed it above several established blockchain platforms.
Just In:📢 #Injective blockchain's TVL hits $31 million, a 22% increase in the past week. 🚀
Injective has now outperformed major #blockchains including Abstract, Swellchain, and Metis in total value locked. 🔥 pic.twitter.com/by9D6WYIAj
— Coinpedia Markets (@MarketCoinpedia) June 12, 2025
This growth reflects confidence in the project’s technology and adoption trends within the decentralized finance space. While the broader market has shown slower movement, Injective has managed to draw in capital steadily.
The recent increase comes amid improving market structure and regulatory clarity in 2025, which analysts believe is fueling adoption. As liquidity deepens across platforms, Injective’s multi-chain compatibility and performance-driven tools appear to be catching investor attention.
Its recent TVL numbers now reflect stronger fundamentals compared to its direct competitors.
INJ Price Holds Steady Around $13
INJ, Injective’s native token, is trading at $13.19 according to CoinGecko, showing a weekly gain of 7.59%.
However, over the last 24 hours, the price declined by 5.55%, with the trading range hovering between $11.31 and $14.26. Despite the recent dip in daily volume, down 14.40%, the token maintains healthy liquidity with over $107 million in transactions in the past day.
Crypto analyst @samaisback noted that INJ’s current price range between $12.90 and $14.02 may serve as a stable entry zone.
With around 99 million tokens in circulation and a market cap near $1.3 billion, the asset shows signs of strength in a transitioning DeFi landscape. He suggests that if Injective continues executing on its roap, mid-term price targets between $16 and $18 are achievable.
Gm 🥷,
Here’s the current update on $INJ, along with insights on what long-term investors should expect:
◾️ Price: Around $13.03, trading within the $12.90–$14.02 intraday range
◾️ Market Cap: Roughly $1.30 billion, with ~99 million $INJ in circulation
◾️ Volume & Action:… pic.twitter.com/QsLatN3o7W
— DΞ'Sama H 🥷 ♟️ (@samaisback) June 12, 2025
Based on current projections, long-term holders could see 2–4x returns by 2028 if DeFi demand continues to rise.
Deflationary tokenomics, paired with Injective’s cross-chain functionality, a bullish thesis for committed investors. Still, the path ahead depends on consistent development, broader DeFi recovery, and Injective’s ability to attract real-world use.
If adoption trends remain stable and new projects continue launching on the network, Injective could strengthen its foothold in the DeFi sector. The blockchain’s growing TVL reflects real activity, not just speculative gains, giving investors reason to stay alert.
